The federal government has named six funds that will be responsible for doling out the $50 million slotted for the life science stream of the renewed VCCI.
Series C financing led by NEA Provides advancement of INV-202 Phase 2 clinical trial in Diabetic Kidney Disease in Q4 Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique